[go: up one dir, main page]

BR112014030835A2 - composição farmacêutica contendo ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal - Google Patents

composição farmacêutica contendo ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal

Info

Publication number
BR112014030835A2
BR112014030835A2 BR112014030835A BR112014030835A BR112014030835A2 BR 112014030835 A2 BR112014030835 A2 BR 112014030835A2 BR 112014030835 A BR112014030835 A BR 112014030835A BR 112014030835 A BR112014030835 A BR 112014030835A BR 112014030835 A2 BR112014030835 A2 BR 112014030835A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
nicotinamide
tryptophan
composition containing
nicotinic acid
Prior art date
Application number
BR112014030835A
Other languages
English (en)
Other versions
BR112014030835B1 (pt
Inventor
Seegert Dirk
Waetzig Georg
Original Assignee
Conaris Res Institute Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conaris Res Institute Ag filed Critical Conaris Res Institute Ag
Publication of BR112014030835A2 publication Critical patent/BR112014030835A2/pt
Publication of BR112014030835B1 publication Critical patent/BR112014030835B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

resumo patente de invenção: "composição farmacêutica contendo ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal". a presente invenção refere-se a uma nova composição farmacêutica que contém ácido nicotínico, nicotinamida, triptofano ou compostos relacionados para influenciar positivamente a microbiota intestinal. em certas modalidades, a composição farmacêutica é parcialmente ou totalmente liberada para o intestino delgado ou intestino grosso. 23264956v1 1/1 23264956v1
BR112014030835-7A 2012-06-15 2013-06-14 Composição contendo ácido nicotínico e/ou nicotinamida e/ou triptofano, e uso da mesma BR112014030835B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102012011890.2 2012-06-15
DE102012011890 2012-06-15
PCT/EP2013/062363 WO2013186355A1 (en) 2012-06-15 2013-06-14 A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota

Publications (2)

Publication Number Publication Date
BR112014030835A2 true BR112014030835A2 (pt) 2017-06-27
BR112014030835B1 BR112014030835B1 (pt) 2022-01-11

Family

ID=47002494

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014030835-7A BR112014030835B1 (pt) 2012-06-15 2013-06-14 Composição contendo ácido nicotínico e/ou nicotinamida e/ou triptofano, e uso da mesma

Country Status (32)

Country Link
US (2) US10426765B2 (pt)
EP (2) EP2861229B1 (pt)
JP (3) JP6855165B2 (pt)
KR (2) KR20150021071A (pt)
CN (2) CN104363907A (pt)
AR (1) AR091465A1 (pt)
AU (1) AU2013276451B2 (pt)
BR (1) BR112014030835B1 (pt)
CA (1) CA2876540C (pt)
CY (1) CY1123999T1 (pt)
DK (1) DK2861229T3 (pt)
ES (1) ES2859758T3 (pt)
HR (1) HRP20210090T1 (pt)
HU (1) HUE053359T2 (pt)
IL (1) IL236205B (pt)
IN (1) IN2014DN10260A (pt)
JO (1) JO3578B1 (pt)
LT (1) LT2861229T (pt)
MX (1) MX370795B (pt)
NZ (1) NZ702297A (pt)
PH (1) PH12014502744A1 (pt)
PL (1) PL2861229T3 (pt)
PT (1) PT2861229T (pt)
RS (1) RS61288B1 (pt)
RU (1) RU2657797C2 (pt)
SA (1) SA113340643B1 (pt)
SG (1) SG11201408251SA (pt)
SI (1) SI2861229T1 (pt)
SM (1) SMT202100248T1 (pt)
TW (1) TWI624260B (pt)
WO (1) WO2013186355A1 (pt)
ZA (1) ZA201408922B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2861229T (lt) 2012-06-15 2021-01-25 Conaris Research Institute Ag Farmacinė kompozicija, apimanti nikotino rūgštį ir (arba) nikotinamidą ir (arba) triptofaną, skirta teigiamai paveikti žarnyno mikrobiotai
PH12015502717B1 (en) * 2013-06-05 2023-09-13 Univ British Columbia Anti-fibrogenic compounds, methods and uses thereof
EP3007680B1 (en) * 2013-06-14 2020-02-19 CONARIS research institute AG Extended release nicotinamide formulation
JP6554468B6 (ja) 2013-12-13 2019-09-11 コナリス リサーチ インスティチュート アーゲー ニコチンアミドと５−アミノサリチル酸との組合せを含有する、腸内微生物叢に有益な影響を及ぼすため、かつ／または胃腸の炎症を処置するための医薬組成物
JP6895752B2 (ja) * 2013-12-13 2021-06-30 コナリス リサーチ インスティチュート アーゲー ニコチン酸および／またはニコチンアミドを含む、腸内微生物叢を改変することにより血中脂質レベルに有益に影響を及ぼすための医薬組成物
EP2884282A1 (en) 2013-12-13 2015-06-17 CONARIS research institute AG Use of tryptophan as a biomarker for patient selection, dosing and therapy monitoring for pharmaceutical compositions targeting the intestinal microbiota in diseases featuring tryptophan deficiency
EP3107553B1 (en) * 2014-02-18 2021-12-01 Universitätsklinikum Jena Methods and compositions for intestinal microenvironment transfer
CN113908074A (zh) * 2014-05-12 2022-01-11 联合利华知识产权控股有限公司 用于诱导抗微生物肽生成的烟酰胺
CN105287561A (zh) * 2015-11-25 2016-02-03 上海交通大学医学院附属瑞金医院 一种治疗溃疡性结肠炎的药物组合物
ES2981479T3 (es) * 2016-04-14 2024-10-09 Chromadex Inc Fórmula para lactantes que comprende ribósido de nicotinamida
KR102381586B1 (ko) 2016-04-19 2022-04-04 훼링 비.브이. 메살라진의 경구용 약제학적 조성물
AU2017252407A1 (en) 2016-04-19 2018-11-01 Ferring B.V. Oral pharmaceutical compositions of nicotinamide
CN109718234A (zh) * 2017-10-31 2019-05-07 中国农业大学 L-色氨酸在缓解肠道炎症反应和屏障功能紊乱中的应用
CN108935981A (zh) * 2018-06-05 2018-12-07 西北农林科技大学 围产期奶山羊添加烟酰胺对羔羊糖脂代谢的影响及其机制
CN113438896B (zh) * 2019-02-12 2024-10-29 田中惠 婴幼儿食品或饮料、用于改善婴幼儿肠道环境的方法和用于增强婴幼儿免疫力的方法
US12357612B2 (en) 2019-03-28 2025-07-15 Tohoku University Prophylactic or therapeutic agent for cancer
CN113398130A (zh) * 2020-03-16 2021-09-17 广州市妇女儿童医疗中心（广州市妇幼保健院、广州市儿童医院、广州市妇婴医院、广州市妇幼保健计划生育服务中心） 烟酰胺用于预防和治疗胃肠道功能紊乱的用途
US20230414599A1 (en) * 2020-11-27 2023-12-28 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections
TW202308605A (zh) * 2021-07-19 2023-03-01 日商明治控股股份有限公司 用於炎症性腸疾病之預防或改善之組合物、以及用於腸內細菌叢調節之組合物
JP2025511241A (ja) * 2022-03-30 2025-04-15 コナリス リサーチ インスティテュート アクチェンゲゼルシャフト 感染症の１種又は複数の急性期後症状を予防又は低減するためのニコチンアミド、ニコチンアミド前駆体、ニコチンアミド代謝体又はその組合せを含む組成物
KR102789810B1 (ko) 2023-02-06 2025-03-31 한림대학교 산학협력단 아토피 피부염 진단용 바이오마커

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE19524928A1 (de) * 1995-07-08 1997-01-09 Basf Ag Verfahren zur Rektifikation von Gemischen hochsiedender luft- und/oder temperaturempfindlicher Substanzen, die eine hohe Trennleistung erfordern, im Feinvakuum, sowie für dieses Verfahren geeignete Kolonnen
US5846983A (en) 1996-02-09 1998-12-08 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
US5736532A (en) * 1996-02-14 1998-04-07 Furda; Ivan Multifunctional fat absorption and blood cholesterol reducing formulation comprising chitosan
GB9614902D0 (en) * 1996-07-16 1996-09-04 Rhodes John Sustained release composition
DE69903661T2 (de) * 1998-12-23 2003-07-03 G.D. Searle Llc, Chicago Kombinationen von ileumgallensäuretransports inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
US6713057B1 (en) 1999-02-24 2004-03-30 The Johns Hopkins University Compositions and methods for modulating serum cholesterol
GB0015242D0 (en) 2000-06-22 2000-08-16 Nycomed Amersham Plc Stabiliser for radiopharmaceuticals
AU2001278699A1 (en) * 2000-08-08 2002-02-18 Shionogi And Co., Ltd. Inflammatory cytokine production inhibitors
US20040185097A1 (en) 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2005072113A2 (en) 2004-01-20 2005-08-11 Harty Richard F Compositions and methods of treatment for inflammatory diseases
US20060264409A1 (en) 2004-01-20 2006-11-23 Harty Richard F Compositions and methods of treatment for inflammatory diseases
EP1751096A4 (en) 2004-05-27 2009-01-07 Antibe Therapeutics Inc 4- OR 5- AMINOSALICYLIC ACID SALT
EP2322146B1 (en) * 2004-09-27 2012-12-12 Sigmoid Pharma Limited Microcapsule formulations comprising two pharmaceutically active ingredients
WO2007004613A1 (ja) * 2005-07-01 2007-01-11 Ajinomoto Co., Inc. 炎症性腸疾患治療薬及びＴＮＦ－α産生抑制剤
AU2007223787A1 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries
ITMI20061932A1 (it) 2006-10-09 2008-04-10 Carlo Ghisalberti Complessi a trasferimento di carica per uso medicale
EP1935422A1 (en) * 2006-12-20 2008-06-25 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Pharmaceutical composition comprising nicotinamide or nicotinic acid
US20090104171A1 (en) * 2007-10-19 2009-04-23 Pardee Joel D Metabolic Enhancement Therapy
EP2276491A4 (en) * 2008-04-25 2011-08-17 Karolinska Inst Innovations Ab NEW THERAPY FOR THE TREATMENT OF IRRITATION SYNDROME
WO2009142731A2 (en) * 2008-05-20 2009-11-26 Cerenis Therapeutics S.A. Niacin and nsaid combination therapy
AU2009256394A1 (en) 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Modified release niacin formulations
EA022886B1 (ru) 2008-10-03 2016-03-31 Др. Фальк Фарма Гмбх Способ поддержания ремиссии язвенного колита у пациентов
JP2011121889A (ja) 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP2012102054A (ja) 2010-11-11 2012-05-31 Kyodo Milk Industry Co Ltd 腸内ポリアミン増強剤
WO2012090224A1 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of mesalamine to be used as improved anti-inflammatory drug
LT2861229T (lt) 2012-06-15 2021-01-25 Conaris Research Institute Ag Farmacinė kompozicija, apimanti nikotino rūgštį ir (arba) nikotinamidą ir (arba) triptofaną, skirta teigiamai paveikti žarnyno mikrobiotai
EP3007680B1 (en) 2013-06-14 2020-02-19 CONARIS research institute AG Extended release nicotinamide formulation
AU2017252407A1 (en) 2016-04-19 2018-11-01 Ferring B.V. Oral pharmaceutical compositions of nicotinamide
US20230414599A1 (en) * 2020-11-27 2023-12-28 Conaris Research Institute Ag Nicotinamide, nicotinamide precursors and nicotinamide metabolites and compositions thereof for reducing the time to resolution of symptoms in patients with covid-19 and other viral infections

Also Published As

Publication number Publication date
EP3831379A1 (en) 2021-06-09
TWI624260B (zh) 2018-05-21
EP2861229A1 (en) 2015-04-22
ES2859758T3 (es) 2021-10-04
JP6855165B2 (ja) 2021-04-07
NZ702297A (en) 2016-11-25
IL236205B (en) 2020-02-27
SA113340643B1 (ar) 2019-10-06
AU2013276451A1 (en) 2015-01-15
CN108273064A (zh) 2018-07-13
WO2013186355A1 (en) 2013-12-19
CA2876540A1 (en) 2013-12-19
JP2015519388A (ja) 2015-07-09
PT2861229T (pt) 2021-01-05
KR102211832B1 (ko) 2021-02-02
CA2876540C (en) 2022-11-29
JP2022017332A (ja) 2022-01-25
HK1204972A1 (en) 2015-12-11
SMT202100248T1 (it) 2021-05-07
PH12014502744A1 (en) 2015-02-02
JP2019069972A (ja) 2019-05-09
SG11201408251SA (en) 2015-01-29
JO3578B1 (ar) 2020-07-05
AR091465A1 (es) 2015-02-04
IN2014DN10260A (pt) 2015-08-07
HUE053359T2 (hu) 2021-06-28
CY1123999T1 (el) 2022-05-27
CN104363907A (zh) 2015-02-18
RU2014148239A (ru) 2016-08-10
AU2013276451B2 (en) 2018-03-29
DK2861229T3 (da) 2021-01-18
US20150126462A1 (en) 2015-05-07
TW201400116A (zh) 2014-01-01
BR112014030835B1 (pt) 2022-01-11
RU2657797C2 (ru) 2018-06-15
MX370795B (es) 2020-01-08
LT2861229T (lt) 2021-01-25
RS61288B1 (sr) 2021-02-26
KR20200011619A (ko) 2020-02-03
US20200009124A1 (en) 2020-01-09
EP2861229B1 (en) 2020-12-23
PL2861229T3 (pl) 2021-08-09
SI2861229T1 (sl) 2021-03-31
US10426765B2 (en) 2019-10-01
IL236205A0 (en) 2015-01-29
MX2014015217A (es) 2015-03-05
ZA201408922B (en) 2016-10-26
KR20150021071A (ko) 2015-02-27
HRP20210090T1 (hr) 2021-03-05

Similar Documents

Publication Publication Date Title
BR112014030835A2 (pt) composição farmacêutica contendo ácido nicotínico e/ou nicotinamida e/ou triptofano para influenciar positivamente a microbiota intestinal
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112014016810A2 (pt) composições e métodos para tratamento de distúrbios metabólicos
MX2014009757A (es) Derivados de isoindolina, composiciones farmaceuticas que los contienen y su uso en terapia.
BR112015014372A2 (pt) inibidores de autotaxina
BR112014031068A2 (pt) derivados piridinona e piridazinona
UA110054C2 (uk) Розгалужені похідні 3-фенілпропіонової кислоти і їх застосування
UA109010C2 (en) Morpholino pyrividines and their use in therapy
GB201106743D0 (en) Novel compounds
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
WO2015086843A3 (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide for beneficially influencing blood lipid levels by modifying the intestinal microbiota
BR112015017251A2 (pt) composições farmacêuticas compreendendo doadores de nitroxil
PH12015500746A1 (en) Benzamides
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
BR112013016590A2 (pt) uso de estabilizantes de glutamina
BR112015000275A2 (pt) utilização de um extrato de mirta como agente anti-biopelícula face p. acnes
PH12016501059A1 (en) A pharmaceutical composition containing combinations of nicotinamide and 5-aminosalicylic acid for beneficially influencing the intestinal microbiota and/or treating gastrointestinal inflammation
PH12015500585A1 (en) Modified hyaluronic acid derivatives and use thereof
BR112015015349A2 (pt) derivado de amida de ácido cinâmico
BR112015014145A2 (pt) compostos antibacterianos
BR112015020566A2 (pt) moduladres de ror gama
BR112015012705A2 (pt) derivados de piridona e usos dos mesmos no tratamento de tuberculose
BR112012022619A2 (pt) composições, métodos, e meios para tratamento da dismenorreia
TR201106224A2 (tr) Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler.
TH1401007439A (th) องค์ประกอบทางเภสัชกรรมที่มีนิโคตินิกแอซิด และ/หรือ นิโคตินาไมด์ และ/หรือ ทริปโตฟานเพื่อการมีอิทธิพลในด้านบวกต่อจุลชีพประจำถิ่นในลำไส้

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2013, OBSERVADAS AS CONDICOES LEGAIS.